Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | terminated | Phase 1 / Phase 2 | 4 | University of UlmOTHER | 2 | May 28, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01149915 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | completed | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00735930 | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2015 | clinicaltrials |
| NCT00210340 | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | withdrawn | Phase 1 | 0 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 0 | Mar 30, 2015 | clinicaltrials |
| NCT00694590 | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00864942 | Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)(Phase I BLR) | completed | Phase 1 | 28 | Georgetown UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | Emory UniversityOTHER | 2 | Mar 10, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT01120457 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | completed | Phase 1 | 96 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | terminated | Phase 1 | 12 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01650727 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | completed | Phase 1 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT00338494 | Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma | completed | Phase 1 | 16 | Yale UniversityOTHER | 1 | Jan 29, 2015 | clinicaltrials |
| NCT00060684 | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | completed | Phase 1 | 30 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT01219010 | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | completed | Phase 1 | 30 | Janssen Research & Development, LLCINDUSTRY | 3 | Jan 19, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00082784 | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | completed | Phase 1 | 93 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01330173 | Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00079716 | Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma | completed | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00968656 | Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1(FISO PET/CT) | completed | Phase 1 | 31 | Washington University School of MedicineOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT00991562 | IMGN901 in Combination With Lenalidomide and Dexamethasone | completed | Phase 1 | 50 | ImmunoGen, Inc.INDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00891137 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | completed | Phase 1 | 30 | Cellerant TherapeuticsINDUSTRY | 1 | Oct 27, 2014 | clinicaltrials |
| NCT00070616 | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support | completed | Phase 1 | 25 | Swedish Orphan BiovitrumINDUSTRY | 0 | Oct 24, 2014 | clinicaltrials |
| NCT02247609 | Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas(4SCAR19273) | unknown | Phase 1 / Phase 2 | 20 | Peking UniversityOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00525447 | Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 | 36 | Seagen Inc.INDUSTRY | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT02248402 | Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma(Vax-DC/MM) | unknown | Phase 1 / Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01504776 | Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)(BUS48T) | completed | Phase 1 | 3 | Anand JillellaOTHER | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | suspended | Phase 1 | 36 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00275080 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2014 | clinicaltrials |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT00729638 | RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 28 | Massachusetts General HospitalOTHER | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00110071 | Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT00621452 | Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2015source: clinicaltrials